BIORCHESTRA creates novel RNA-based therapeutics that will usher in a new era of treatment for neurodegenerative diseases.
BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 22, 2022 | Series C | $45M | 12 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
GS Holdings | — | Series C |
E&Venture Partners | — | Series C |
Widwin Investment | — | Series C |
Chong Kun Dang Pharmaceutical Corp. | — | Series C |
Dayli Partners | — | Series C |
IMM Investment | — | Series C |
LSK Investment | — | Series C |
NH Investment & Securities | — | Series C |
Quantum Ventures Korea | — | Series C |
SBI Investment | — | Series C |